Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Neurosense Therapeutics Ltd (NRSN)

Neurosense Therapeutics Ltd (NRSN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS PR Newswire - Wed Feb 18, 8:05AM CST

CAMBRIDGE, Mass. , Feb. 18, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.  (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying...

NRSNW : 0.2090 (+10.06%)
NRSN : 0.8660 (+1.38%)
NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition PR Newswire - Mon Feb 9, 8:20AM CST

Strengthens Global IP Portfolio for PrimeC Through 2042

NRSN : 0.8660 (+1.38%)
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease PR Newswire - Wed Jan 21, 7:30AM CST

CAMBRIDGE, Mass. , Jan. 21, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.  (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...

NRSNW : 0.2090 (+10.06%)
NRSN : 0.8660 (+1.38%)
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB PR Newswire - Thu Jan 8, 7:45AM CST

Alzheimer's Clinical and Biomarker Outcomes Expected in Q1 2026

NRSNW : 0.2090 (+10.06%)
NRSN : 0.8660 (+1.38%)
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study PR Newswire - Mon Dec 22, 2025

Clinical and Biomarker Outcomes Expected to Be Reported in Q1 2026

NRSN : 0.8660 (+1.38%)
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026 PR Newswire - Thu Dec 4, 2025

CAMBRIDGE, Mass. , Dec. 4, 2025 /PRNewswire/ --  NeuroSense Therapeutics Ltd.  (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...

NRSNW : 0.2090 (+10.06%)
NRSN : 0.8660 (+1.38%)
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS PR Newswire - Mon Nov 24, 2025

CAMBRIDGE, Mass. , Nov. 24, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.  (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...

NRSN : 0.8660 (+1.38%)
NeuroSense to Host Investor Webinar on December 8, 2025 PR Newswire - Mon Nov 3, 2025

Business, regulatory and clinical updates will be provided

NRSNW : 0.2090 (+10.06%)
NRSN : 0.8660 (+1.38%)
Neurosense Therapeutics Ltd. (NRSN) Receives a New Rating from Noble Financial Tipranks - Fri Oct 17, 2025

Neurosense Therapeutics Ltd. received a Buy rating and a $9.00 price target from Noble Financial analyst Robert LeBoyer on October 14. The company’s shares closed yesterday at $1.24.Elevate Your Investing...

NRSN : 0.8660 (+1.38%)
NeuroSense Announces Promising Alzheimer’s Biomarker Reductions with PrimeC Tipranks - Tue Oct 7, 2025

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Neurosense...

NRSN : 0.8660 (+1.38%)

Barchart Exclusives

1 Little-Known Tech Stock That Wedbush Calls a Must-Own Amid Middle East Conflict Barchart - Sat Mar 7, 10:30AM CST
Check Point emerges as a must-own cybersecurity stock amid Middle East tensions, offering stable AI-driven growth. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot